This study looks at treating urothelial carcinoma, a type of bladder cancer, using medicines called immune checkpoint inhibitors (ICI) with or without a drug named propranolol hydrochloride. Immune checkpoint inhibitors help the immune system fight cancer. Propranolol is usually used for heart conditions but might help cancer treatment too. The study is open label, meaning both doctors and patients know what treatment is being given.
The main goal is to check if using propranolol with ICIs is safe and to see how well it helps treat the cancer. Participants will be divided into two groups: one will receive ICIs with propranolol, and the other will receive ICIs alone. ICIs used are Pembrolizumab, Avelumab, and Nivolumab.
- The study lasts up to 2 years with follow-up every 12 weeks.
- Participants must be at least 18 years old and meet specific health criteria.
- Safety and side effects will be closely monitored throughout the study.
How understandable was the trial content above?
Hard to understand
Easy to understand